Login to Your Account

Clinic Roundup

Monday, January 3, 2011
Immunitor USA Inc., of College Park, Md., has published data from the first half of the 120-patient imm01 Phase IIb trial of its V5 immunomodulator product for tuberculosis, including difficult-to-treat forms of the disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription